Daniel Karp

Daniel leads our global business development team, which includes mergers & acquisitions, licensing, collaborations, alliance management, and integration. Under his leadership, the team evaluates external opportunities and executes business development transactions.  These deals drive growth and accelerate Organon’s strategy by building the company’s pipeline and portfolio.

Prior to joining Organon, Daniel served as Executive Vice President, Corporate Development at Biogen. Previously, he held a number of positions of increasing responsibility at Pfizer, including VP, Head of BD for Worldwide Research & Development, and VP, Head of BD for Pfizer Vaccines, Oncology and Consumer Healthcare. Throughout his career, Daniel and his teams have executed M&A and collaboration deals totaling over $80B in potential value. Most importantly, these transactions have brought new drugs, gene therapies, vaccines, devices, and technologies closer to the patients who need them. Earlier in his career, Daniel held roles in healthcare and life sciences strategy consulting.

Daniel has a B.S. in biology from Duke University and an M.B.A. from the Wharton School of the University of Pennsylvania. Currently, he serves as Director on the board of Cartesian Growth Corp II and previously served on the board of Cartesian Growth Corp, which combined with Tiedemann Group and Alvarium Investments.